AbbVie Stemcentrx LLC
Records under this name other than the patents AbbVie Stemcentrx LLC holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 16 patents it holds.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,035,853 | Site-Specific Antibody Conjugation Methods and Compositions Lapsed on the fee record Ended Jul 31, 2026 · High confidence | Lapsed on the fee record | Ended Jul 31, 2026 | High confidence |
| US 9,914,784 | PTK7 modulators and methods of use Lapsed on the fee record Ended Mar 13, 2026 · From the USPTO record | Lapsed on the fee record | Ended Mar 13, 2026 | From the USPTO record |
| US 9,878,053 | Methods of delivering DLL3 antibody drug conjugates Lapsed on the fee record Ended Jan 30, 2026 · From the USPTO record | Lapsed on the fee record | Ended Jan 30, 2026 | From the USPTO record |
| US 9,867,887 | Anti-DLL3 antibody drug conjugates Lapsed on the fee record Ended Jan 16, 2026 · From the USPTO record | Lapsed on the fee record | Ended Jan 16, 2026 | From the USPTO record |
| US 9,861,708 | Kits containing DLL3 antibody drug conjugates Lapsed on the fee record Ended Jan 9, 2026 · From the USPTO record | Lapsed on the fee record | Ended Jan 9, 2026 | From the USPTO record |
| US 9,855,343 | Anti-DLL3 antibody drug conjugates Lapsed on the fee record Ended Jan 2, 2026 · From the USPTO record | Lapsed on the fee record | Ended Jan 2, 2026 | From the USPTO record |
| US 9,775,916 | Anti-DLL3 antibody drug conjugates for treating cancer Lapsed on the fee record Ended Oct 3, 2025 · From the USPTO record | Lapsed on the fee record | Ended Oct 3, 2025 | From the USPTO record |
| US 9,770,518 | Anti-DLL3 antibody drug conjugates Lapsed on the fee record Ended Sep 26, 2025 · From the USPTO record | Lapsed on the fee record | Ended Sep 26, 2025 | From the USPTO record |
| US 9,764,042 | Methods of making DLL3 antibody drug conjugates Lapsed on the fee record Ended Sep 19, 2025 · From the USPTO record | Lapsed on the fee record | Ended Sep 19, 2025 | From the USPTO record |
| US 9,486,537 | Anti-DLL3 antibody drug conjugates Lapsed on the fee record Ended Nov 8, 2024 · From the USPTO record | Lapsed on the fee record | Ended Nov 8, 2024 | From the USPTO record |